DEFA14A: Bausch + Lomb Amends Proxy Statement Ahead of 2025 Annual Meeting

Bausch + Lomb updates its proxy statement to reflect agreements between its majority shareholder, Bausch Health Companies Inc., and certain shareholder groups regarding board representation and voting.

Summary

• Bausch + Lomb Corporation has amended its definitive proxy statement related to the 2025 Annual Meeting of Shareholders.
• The meeting will be held virtually on May 21, 2025, at 10:30 a.m. Eastern Daylight Time.
• The amendment reflects letter agreements between Bausch Health Companies Inc. (BHC), the majority shareholder of Bausch + Lomb, and several shareholder groups: the Icahn Group, the Paulson Group, and the Kavanagh Group.
• These agreements stipulate that if any of these groups engage in 'Specified Actions' (such as instigating a proxy contest against BHC), they must tender their resignations from both the BHC and Bausch + Lomb Boards of Directors.
• BHC has agreed to vote in favor of the Group Designees nominated to the Bausch + Lomb Board, provided no member of the group has engaged in a Specified Action.
• The company is waiving the proxy deadline in connection with this amendment.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining agreements to manage shareholder relations. It suggests a proactive approach to governance, which is generally viewed positively, but also hints at potential underlying tensions with activist investors.

Positives

• The agreements provide clarity and structure around the relationship between Bausch Health Companies Inc. and key shareholder groups.
• The agreements aim to prevent disruptive actions such as proxy contests against Bausch Health Companies Inc.

Negatives

• The agreements could be seen as limiting the influence of certain shareholder groups on the Bausch + Lomb board if they engage in actions deemed 'Specified Actions'.

Risks

• The definition of 'Specified Actions' could be interpreted differently, leading to potential disputes.
• The agreements rely on the continued cooperation between Bausch Health Companies Inc. and the shareholder groups.

Future Outlook

The agreements aim to ensure stability in board representation and voting for the upcoming annual meeting and potentially beyond, contingent on the actions of the involved shareholder groups.

Industry Context

This announcement reflects a trend of companies seeking to manage relationships with activist investors and major shareholders through formal agreements to avoid proxy battles and ensure board stability.

Comparison to Industry Standards

• Companies like Procter & Gamble and Pershing Square Capital Management have used similar agreements to manage board representation and shareholder activism.
• These agreements are often compared to standstill agreements, which are common in situations where a company wants to limit a shareholder's ability to increase their stake or launch a proxy fight.
• The specific terms of these agreements, such as the definition of 'Specified Actions', are tailored to the unique circumstances of each company and its shareholders.

Stakeholder Impact

• Shareholders: The agreements could impact the influence of certain shareholder groups on the board.
• Board of Directors: The agreements outline conditions for board representation.
• Bausch Health Companies Inc.: The agreements define voting rights and responsibilities.

Next Steps

• Shareholders should review the amended proxy statement before voting.
• The company will hold its Annual Meeting of Shareholders on May 21, 2025.
• Monitor the actions of the Icahn Group, Paulson Group, and Kavanagh Group to ensure compliance with the letter agreements.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Bausch + Lomb, Bausch Health, Shareholders, Board of Directors, Voting Agreement, Icahn Group, Paulson Group, Kavanagh Group